Drugs and Substitutes in Medical Store

Authors

  • P Sumalatha  Associate Professor, Department of CSE, Bhoj Reddy Engineering College for Women, Hyderabad, India
  • M Akanksha  U.G. Scholar, Department of CSE, Bhoj Reddy Engineering College for Women, Hyderabad, India
  • Maria Fatima  U.G. Scholar, Department of CSE, Bhoj Reddy Engineering College for Women, Hyderabad, India

Keywords:

Brand Names, Generic, Therapeutic

Abstract

A very large part of India’s population fulfils its healthcare needs from government run healthcare delivery system which is free, contributory or highly subsidised. Use of medicines forms a large part of healthcare facility. As the number of medicines and brands are ever increasing in today’s market, it is usual for pharmacy to substitute a generic instead of the prescribed brand or a different brand if the prescribed brand is not available. Depending on the type of substitute, it could fall under ‘generic’ or ‘therapeutic’ substitution. For any condition, there may be numerous medicines existing, some of which probably got introduced more recently, may be more expensive and erroneously perceived to act better than the earlier known medications for the same ailment. Also, due to very high number of medicines that are approved and available for use in the market, it is impossible to stock all the medicines in any pharmacy. Generic and therapeutic substitutions should be formalised and implemented by institutions, with the consent and cooperation of all the stake holders as guided by World Health Organisation. The advantages and limitations of medicines substitutions are discussed in the review.

References

  1. Zetterqvist AV, Merlo J, Mulinari S. Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004–2012: A quantitative and qualitative study of pharmaceutical industry self-regulation. PLoS Med. 2015;12(2):e1001785.
  2. Bajpai V. The challenges confronting public hospitals in india, their origins, and possible solutions. Advances in Public Health. 2014
  3. Reghu R, Vijayan M, Roshni PR. Procurement and distribution of medicines in government hospitals of Tamil Nadu - An overview. International Journal of Research in Pharmaceutical Sciences. 2013;( 4):96-100.
  4. Wangu MM, Osuga BO. Availablity of essential medicines in public hospitals: A study of selected public hospitals in Nakuru County, Kenya. African Journal of Pharmacy and Pharmacology. 2014;8(17):438-42.
  5. Johnston A, Asmar R, Dahlof B, Hill K, Jones DA, Jordan J, et al. Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe. Br J Clin Pharmacol. 2011;72:727–30.
  6. O'Leary A, Usher C, Lynch M, Hall M, Hemeryk L, Spillane S, et al. Generic medicines and generic substitution: contrasting perspectives of stakeholders in Ireland. BMC Res Notes. 2015;8(1):790.
  7. Guidelines for Bioavailability and Bioequivalence Studies. Central Drugs Control Organisation, Ministry of Health and Family Affairs, Govt of India, New Delhi.[Cited in 2017]. Available from: http://cdsco.nic.in/html/be%20guidelines%20draft%20ver10%20march%2016,%2005.pdf
  8. European Medicines Agency. Guideline on similar biological medicinal products. November 2004. [Cited in 2017]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf.
  9. Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol. 2010;70(3):335–41.
  10. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JPT. Evaluating the evidence from a network meta-analysis. PLoS ONE. 2014;9:e99682.
  11. Samra SS, Dongre N, Ballary C, Desai A. Comparison of the efficacy, safety and tolerability of telmisartan with losartan in Indian patients with mild to moderate hypertension: a pilot study. J Indian Med Assoc. 2003;101(5):327-28.
  12. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(5):283-91, 318.
  13. Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev. 2014;11:CD010254.
  14. Park JH, Park H, Lee DH, Sung IK. A randomized, double blinded, clinical trial to assess the efficacy and cost effectiveness of omeprazole compared to rabeprazole in the maintenance therapy of patients with gastroesophageal reflux disease. J Neurogastroenterol Motil. 2013;19(2):219-26.
  15. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297-309.

International Journal of Scientific Research in Science, Engineering and Technology

Downloads

Published

2023-04-30

Issue

Volume 10, Issue 2, March-April-2023

Section

Research Articles

License

Copyright (c) IJSRSET

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
P Sumalatha, M Akanksha, Maria Fatima "Drugs and Substitutes in Medical Store" International Journal of Scientific Research in Science, Engineering and Technology (IJSRSET), Print ISSN : 2395-1990, Online ISSN : 2394-4099, Volume 10, Issue 2, pp.462-466, March-April-2023.